Background: We previously reported an increased risk of all-cause and AIDS mortality among HIV-infected women with albuminuria (proteinuria or microalbuminuria) enrolled in the Women's Interagency HIV Study (WIHS) prior to the introduction of HAART. Methods: The current analysis includes 1,073 WIHS participants who subsequently initiated HAART. Urinalysis for proteinuria and semi-quantitative testing for microalbuminuria from two consecutive study visits prior to HAART initiation were categorized as follows: confirmed proteinuria (both specimens positive for protein), confirmed microalbuminuria (both specimens positive with at least one microalbuminuria), unconfirmed albuminuria (one specimen positive for proteinuria or microalbuminuria), or negative (both specimens negative). Time from HAART initiation to death was modelled using proportional hazards analysis. Results: Compared with the reference group of women with two negative specimens, the hazard ratio (HR) for all-cause mortality was significantly increased for women with confirmed microalbuminuria (HR 1.9, 95% CI 1.2-2.9). Confirmed microalbuminuria was also independently associated with AIDS death (HR 2.3, 95% CI 1.3-4.3), whereas women with confirmed proteinuria were at increased risk for non-AIDS death (HR 2.4, 95% CI 1.2-4.6). Conclusions: In women initiating HAART, pre-existing microalbuminuria independently predicted increased AIDS mortality, whereas pre-existing proteinuria predicted increased risk of non-AIDS death. Urine testing may identify HIV-infected individuals at increased risk for mortality even after the initiation of HAART. Future studies should consider whether these widely available tests can identify individuals who would benefit from more aggressive management of HIV infection and comorbid conditions associated with mortality in this population.
Introduction
The current analysis investigates whether pre-existing microalbuminuria also predicts mortality among HIVinfected women who initiate HAART.
Methods
The Women's Interagency HIV Study (WIHS) has been described previously [6] . Briefly, HIV-infected and highrisk seronegative women were enrolled from six sites in the United States. Social and medical history, HIV RNA, CD4 + T-cell count, haemoglobin, serum albumin and urinalysis were ascertained at enrolment and every 6 months. Hepatitis serologies and serum creatinine were performed at enrolment, and creatinine was repeated annually. Glomerular filtration rate (GFR) was estimated using the 4-variable Modification of Diet in Renal Disease (MDRD) equation [7] . The institutional review board of each site approved the WIHS protocol, and participants provided written informed consent.
Urine specimens were collected every 6 months for the first 3 years and stored at -70ºC in a central repository. Specimens were excluded if there was evidence of cystitis, as previously described [5] . Semi-quantitative microalbuminuria testing (Clinitek Microalbumin Reagent Strips and Clinitek 50 Analyzer; Siemens Healthcare Diagnostics, Deerfield, IL, USA) was performed in banked specimens from the first two eligible visits for each participant. Quality assurance testing was performed using standardized controls (Bio-Rad Laboratories, Hercules, CA, USA). Microalbuminuria was defined as an albumin:creatinine ratio >30 mg/g (3.4 mg/mmol). Women with urinalysis protein ≥1+ at both visits were considered to have confirmed proteinuria. Women with microalbuminuria at both visits or with microalbuminuria at one visit and proteinuria at the other were considered to have confirmed microalbuminuria. Women with proteinuria or microalbuminuria at only one visit were considered to have unconfirmed albuminuria. This analysis excluded women who initiated HAART prior to the second urine visit. Among included participants, the median time from the second urine visit to HAART initiation was 728 days.
Data on vital status and date of death were collected from medical records, providers, personal contacts and the National Death Index. Cause of death was ascertained from the death certificate, medical records, providers or personal contacts, in that order, and categorized as AIDS or non-AIDS using previously described methods [8] .
HIV-infected women enrolled between 1994 and 1995 who subsequently initiated HAART were included in this analysis. Sustained HAART use was defined as self-reported use for ≥3 consecutive visits prior to March 2009. The date of HAART initiation was defined as the mid-point between the last pre-HAART visit and the first visit at which HAART use was reported. Women with >2 missed visits between the last pre-HAART visit and the first HAART visit were excluded. Continuous and categorical variables were compared by level of albuminuria using KruskalWallis and χ 2 tests, respectively. A two-sided P-value of <0.05 was considered significant. Kaplan-Meier and proportional hazards models evaluated the association of albuminuria with time from HAART initiation to death. Multivariate models were adjusted for demographics and laboratory results at the last pre-HAART visit (age, race ethnicity, log transformed HIV RNA, CD4 + T-cell count, haemoglobin, serum albumin and GFR), as well as for relevant clinical conditions (hepatitis C coinfection, diabetes and blood pressure). Prior AIDS-defining illness (ADI) was ascertained at the first HAART visit in order to include events that prompted initiation. When data were missing, the value was obtained from the most recent prior visit. All analyses were performed using SAS (version 9.1.3; SAS Institute, Inc., Cary, NC, USA).
Results
A total of 2,059 HIV-infected women were enrolled in WIHS between 1994 and 1995. Among the 1,390 participants who subsequently initiated HAART during the study period, 1,073 (77%) were included in this analysis. Women were excluded if they initiated HAART prior to the second urine visit (n=54), had <2 eligible urine specimens (n=206) or had >2 missed visits between the last pre-HAART visit and the first HAART visit (n=57). Excluded women were similar with respect to age and race ethnicity (QS et al., data not shown).
Among included participants, 107 (10%) had unconfirmed albuminuria, 42 (4%) had confirmed microalbuminuria and 33 (3%) had confirmed proteinuria. Albuminuria was associated with Black race, as well as with GFR<60 ml/min/1.73 m 2 , higher HIV RNA, higher blood pressure, and lower haemoglobin and serum albumin at the last pre-HAART visit (Table 1) .
There were 301 deaths during the study period, including 130 AIDS deaths and 171 non-AIDS deaths (Table 1 ). Figure 1 shows the time to all-cause, AIDS and non-AIDS death following HAART initiation. Compared with the reference group of women with no albuminuria, women with confirmed microalbuminuria had the highest risk for all-cause mortality (hazard ratio [HR] 3.0, 95% CI 2.0-4.6), followed by those with confirmed proteinuria (HR 2.3, 95% CI 1.4-3.9). Only confirmed microalbuminuria was significantly associated with AIDS death when considered separately ( Figure 1B ), whereas women with either confirmed microalbuminuria or confirmed proteinuria were at increased risk for non-AIDS death ( Figure 1C ). Women with a single episode of albuminuria were at modestly increased risk for all-cause mortality (HR 1.6, 95% CI 1.1-2.2), but unconfirmed albuminuria was not statistically associated with AIDS or non-AIDS death.
In multivariate analysis (Table 2) , confirmed microalbuminuria remained significantly associated with allcause (HR 1.9, 95% CI 1.2-2.9) and AIDS mortality (HR 2.3, 95% CI 1.3-4.3), but the association with non-AIDS death was no longer significant. Only the association of confirmed proteinuria with non-AIDS death remained significant (HR 2.4, 95% CI 1.2-4.6). In addition to albuminuria, the only other factor that was independently associated with time to both AIDS and non-AIDS death was GFR<60 ml/min/1.73 m 2 . Results were similar when the CKD-EPI equation [9] was used to estimate GFR (QS et al., data not shown). Other factors independently associated with AIDS death included CD4 + T-cell count, HIV RNA and haemoglobin levels prior to HAART initiation (Table 2) . Factors associated with non-AIDS death included older age, hepatitis C coinfection, current smoking and lower serum albumin. Although CD4 + T-cell count, HIV RNA and time to HAART initiation did not predict non-AIDS death, history of ADI remained marginally associated with non-AIDS mortality.
Discussion
We have previously demonstrated an increased risk of all-cause and AIDS-related mortality among HIVinfected women with microalbuminuria prior to the introduction of HAART [5] . In the current analysis of 1,073 HIV-infected women who subsequently initiated HAART, pre-existing microalbuminuria was associated with a similar twofold increase in the risk of allcause and AIDS death. These observations suggest that screening for albuminuria may identify HIV-infected Race, hepatitis B status, diabetes, blood pressure and time to HAART initiation were not retained in the final multivariate models, which were based on stepwise selection with a P-value <0.05 for retention. GFR, estimated glomerular filtration rate; hepatitis C coinfection, hepatitis C antibody positive and RNA positive or unknown. individuals at increased risk for mortality even after HAART initiation.
Chronic kidney disease (CKD), as indicated by overt proteinuria or decreased GFR, has been associated with increased mortality in the general population and in HIV-infected women [10] [11] [12] [13] . In an earlier analysis of WIHS censored in 2002, proteinuria detected by routine urinalysis was associated with a more than twofold increased risk of all-cause mortality among women who initiated HAART, although deaths were not classified by relationship to AIDS [11] . More recently, studies in predominantly male populations have demonstrated associations between overt proteinuria and cardiovascular events in HIV-infected individuals [14, 15] . Although detailed data on cause of death were not available for the current analysis, cardiovascular disease was a common cause of non-AIDS mortality in an earlier analysis of WIHS [16] . Future studies should consider whether HIV-infected individuals with overt proteinuria would benefit from more intensive management of cardiovascular risk factors and other comorbidities that may contribute to non-AIDS mortality.
Microalbuminuria has also been associated with mortality and cardiovascular disease in HIV-negative patient populations [4] . Although microalbuminuria may indicate early CKD, it has also been hypothesized to reflect systemic inflammation [3] and generalized endothelial dysfunction [4] . In a prior analysis of 162 WIHS participants with serial albuminuria measurements, albuminuria stabilized in women who initiated HAART, but continued to increase in untreated controls [17] . Microalbuminuria was hypothesized to reflect inflammation and endothelial dysfunction resulting from active viral replication. The results of the current analysis suggest that pre-existing microalbuminuria may continue to predict AIDS-related outcomes even after the initiation of HAART.
Future studies are needed to determine whether microalbuminuria predicts mortality in HIV-infected men or from specific causes. Other important limitations are the possible underestimation of albuminuria in women taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers, and the misclassification of women who developed new albuminuria in the interval between the confirmatory urine test and HAART initiation. Misclassification may also have occurred due to the limited sensitivity of dipstick assays to detect lower levels of proteinuria [18] and microalbuminuria, or due to decreased sensitivity of microalbuminuria testing in banked urine [19] . These types of misclassification, however, would be expected to bias our results towards the null. Finally, we had limited power to exclude an association between overt proteinuria and AIDS mortality or to evaluate the effect of individual ART regimens.
The current study suggests that albuminuria testing before initiation of HAART may identify individuals at increased risk for mortality despite HAART. Screening for CKD, including assessment for overt proteinuria, is currently standard of care in HIV-infected individuals [20] . Future studies should investigate whether additional microalbuminuria testing is a cost-effective approach to identify high-risk patients, who may benefit from more aggressive management of comorbidities and behavioral factors known to contribute to mortality.
